title: Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid.
abstract: Radionuclide scanning with tumour-seeking agents such as pentavalent technetium-99m dimercaptosuccinic acid [99mTc(V)-DMSA], thallium-201 and technetium-99m sestamibi (MIBI) has been reported to be useful in the detection of medullary thyroid carcinoma (MTC). We undertook a study in 14 MTC patients to determine the comparative imaging potential of 201Tl, MIBI and 99mTc(V)-DMSA in the detection of recurrent or metastatic MTC. All patients underwent total thyroidectomy and had persistently elevated serum calcitonin levels after the surgery. Scintigraphic studies were carried out 20 min after the injection of 111 MBq of 201Tl or 555 MBq of MIBI and 2 h following the injection of 370 MBq of 99mTc(V)-DMSA. All scintigraphic findings were correlated with contemporaneous CT or MRI studies. CT, MRI and bone scans showed 42 (26 bone, 16 soft tissue) metastatic sites in 11 of the 14 patients. In the remaining three patients no lesions were detected during diagnostic evaluation. 99mTc(V)-DMSA showed all of the soft tissue metastases but could not show two bone lesions. On the other hand, MIBI imaging was false-negative in 22 (52%) sites and 201Tl was false-negative in 34 (80%) sites. Overall, lesion detection sensitivities for 99mTc(V)-DMSA, MIBI and 201Tl were 95%, 47% and 19% respectively. We conclude that 99mTc(V)-DMSA is clearly superior to MIBI and 201Tl in the follow-up of MTC patients.
authors.affiliation: Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Ugur
authors.forename: L
authors.initials: L
authors.lastname: Kostakğlu
authors.forename: N
authors.initials: N
authors.lastname: Güler
authors.forename: B
authors.initials: B
authors.lastname: Caner
authors.forename: U
authors.initials: U
authors.lastname: Uysal
authors.forename: N
authors.initials: N
authors.lastname: Elahi
authors.forename: M
authors.initials: M
authors.lastname: Haliloğlu
authors.forename: D
authors.initials: D
authors.lastname: Yüksel
authors.forename: T
authors.initials: T
authors.lastname: Aras
authors.forename: H
authors.initials: H
authors.lastname: Bayhan
authors.forename: C
authors.initials: C
authors.lastname: Bekdik
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002116:Calcitonin / Q000097:blood; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging* / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D015609:Organotechnetium Compounds; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D012983:Soft Tissue Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D004113:Succimer; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D017256:Technetium Tc 99m Sestamibi; D013794:Thallium Radioisotopes; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology
chemical_list: D015609:Organotechnetium Compounds; D013794:Thallium Radioisotopes; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D002116:Calcitonin; D017256:Technetium Tc 99m Sestamibi; D004113:Succimer